Information Prompts Individuals to Consult Physician, Inform Relatives
Mountain View, Calif. — February 12, 2013 —
A 23andMe study of consumers’ reactions to genetic testing found that even when the tests revealed high-risk mutations in individuals, those individuals had few negative reactions to the news. Instead of inducing serious anxiety, the test results prompted people to take positive steps, including follow-up visits with a doctor and discussions with family members who could also be at risk.
The study, titled “Dealing with the unexpected: Consumer responses to direct-access BRCA
mutation testing” published today as part of the launch of PeerJ, a new peer-reviewed open-access journal in which all articles are freely available to everyone (https://PeerJ.com
“The paper addresses one of the most urgent questions in the field of genetics and genomics, namely the impact of receiving unexpected information about high genetic risk for a life-threatening disease,” said the lead author of the paper and 23andMe’s Senior Medical Director Dr. Uta Francke.
The study looked at how people reacted when they learned for the first time that they carried a mutation in either the BRCA1
gene that put them at higher risk for breast and ovarian cancer. The study included interviews conducted with 32 individuals found to be mutation carriers and 31 individuals found to be non-carriers. Five to ten percent of breast cancers occur in women with a genetic predisposition for the disease, usually due to mutations in either the BRCA1
gene. The mutations at the center of this study are responsible for a substantial number of hereditary breast and ovarian cancers among women with Ashkenazi Jewish ancestry.
Those who acquired the potentially life-saving information not only took appropriate actions on their own behalf, but also notified relatives who might share that risk. In what the study described as a “cascading effect,” a number of relatives who were subsequently tested discovered they too had one of the mutations.
The findings are important given that a frequent concern regarding direct-to-consumer testing is based on the assumption that it causes either serious emotional distress or triggers deleterious actions on the part of consumers. Individuals who learned they had the mutation said they did not suffer serious emotional distress, and did not take inappropriate actions. All but one of the 32 mutation-positive participants appreciated learning their BRCA
mutation status. None of the 31 mutation-negative individuals misinterpreted their result to think they are free from all risks and safe to abandon routine cancer screening.
The study provides important preliminary data that suggest some of the bioethical concerns may be overstated, at least for the self-selected pool of individuals who seek DTC personal genomics information. The authors suggested that broader screening of Ashkenazi Jewish women for these three BRCA
mutations should be considered.”
Link to the Published Version of the article: https://peerj.com/articles/8
Competing Interests Statement (from the article):
“UF, AKK, NE, BM, JYT and JLM are and CD was employed by 23andMe. UF, AKK, NE, BM, JYT and JLM hold stock options in the company. UF is an Academic Editor on PeerJ.”
Funding Statement (from the article):
“This work was supported by 23andMe, Inc. “Funding” consisted of the company paying the authors’ salaries, the transcription service and Amazon gift certificates to participants who completed the phone interviews. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”
Ethical Approval (from the article):
“The following information relates to ethical approvals: AAHRPP-accredited Ethical & Independent Review Services Institutional Review Board (E&I Review Document IRB-1-02.5).”
Handling Academic Editor
(conducted the peer review and approved the publication): Jennifer Wagner, Center for the Integration of Genetic Healthcare Technologies, Division of Translational Medicine and Human Genetics, University of Pennsylvania
Abstract (from the article)
gene mutations convey a high risk for breast and ovarian cancer, but current guidelines limit BRCA
mutation testing to women with early-onset cancer and relatives of mutation-positive cases. Benefits and risks of providing this information directly to consumers are unknown.
To assess and quantify emotional and behavioral reactions of consumers to their 23andMe Personal Genome Service report of three BRCA
mutations that are common in Ashkenazi Jews, we invited all 136 BRCA1
mutation-positive individuals in the 23andMe customer database who had chosen to view their BRCA
reports to participate in this IRB-approved study. We also invited 160 mutation-negative customers who were matched for age, sex and ancestry. Semi-structured phone interviews were completed for 32 mutation carriers, 16 women and 16 men, and 31 non-carriers. Questions addressed personal and family history of cancer, decision and timing of viewing the BRCA
report, recollection of the result, emotional responses, perception of personal cancer risk, information sharing, and actions taken or planned.
Eleven women and 14 men had received the unexpected result that they are carriers of a BRCA1
185delAG or 5382insC, or BRCA2
6174delT mutation. None of them reported extreme anxiety and four experienced moderate anxiety that was transitory. Remarkably, five women and six men described their response as neutral. Most carrier women sought medical advice and four underwent risk-reducing procedures after confirmatory mutation testing. Male carriers realized that their test results implied genetic risk for female relatives, and several of them felt considerably burdened by this fact. Sharing mutation information with family members led to screening of at least 30 relatives and identification of 13 additional carriers. Non-carriers did not report inappropriate actions, such as foregoing cancer screening. All but one of the 32 mutation-positive participants appreciated learning their BRCA
Direct access to BRCA
mutation tests, considered a model for high-risk actionable genetic tests of proven clinical utility, provided clear benefits to participants. The unexpected information demonstrated a cascade effect as relatives of newly identified carriers also sought testing and more mutation carriers were identified. Given the absence of evidence for serious emotional distress or inappropriate actions in this subset of mutation-positive customers who agreed to be interviewed for this study, broader screening of Ashkenazi Jewish women for these three BRCA
mutations should be considered.
PeerJ is an Open Access publisher of scholarly scientific content, which offers researchers a lifetime membership, for a single low price, giving them the ability to openly publish all future articles for free. The launch of PeerJ occurred on February 12th, 2013 with the publication of 30 articles. PeerJ is based in San Francisco, CA and London, UK and can be accessed at https://peerj.com/
All works published in PeerJ are Open Access and published using a Creative Commons license (CC-BY 3.0). Everything is immediately available—to read, download, redistribute, include in databases and otherwise use—without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed.
PeerJ Media Resources (including logos) can be found at: https://peerj.com/about/press/
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. The company was named by TIME as a “Genius Company” in 2018, and featured as Fast Company's #2 Most Innovative Health Company in 2018. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Sunnyvale, CA. More information is available at www.23andMe.com.